Berlin, 10.10.2002. NEMOD Immuntherapie AG, Berlin, a participation of Eckert & Ziegler AG (ISIN DE 0005659700) and Immuno-Designed Molecules S.A., Paris, have signed a comprehensive cooperation agreement for the evaluation and development of certain key components for an ex-vivo cell based cancer therapeutic.
The contract grants IDM access to the services of NEMOD's development team and to a number of highly specific pan-carcinomic antibodies that have been developed by NEMOD as transport vehicles for various applications. The antibodies target, among others, unique glycosylation pattern on tumor cell membranes, and could serve as a vehicle for IDM proprietary Monocytes-derived Activated Killer cells (MAK®).
For its services and intellectual property NEMOD will receive from IDM certain service fees, and, depending on the progress of the development work, royalty income and milestone payments.
"The co-operation is a further validation of the value of NEMOD's extensive glycobiology know-how", explains Andreas Hey, COO of NEMOD. "it opens the way to leverage NEMOD's antibody expertise into pharmaceutical product development".
The Board of Directors